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Sterols are constituents of the cellular membranes that are essential for their normal structure and function. In mammalian cells,
cholesterol is the main sterol found in the various membranes. However, other sterols predominate in eukaryotic microorganisms
such as fungi and protozoa. It is now well established that an important metabolic pathway in fungi and in members of the
Trypanosomatidae family is one that produces a special class of sterols, including ergosterol, and other 24-methyl sterols, which
are required for parasitic growth and viability, but are absent from mammalian host cells. Currently, there are several drugs that
interfere with sterol biosynthesis (SB) that are in use to treat diseases such as high cholesterol in humans and fungal infections.
In this review, we analyze the eﬀects of drugs such as (a) statins, which act on the mevalonate pathway by inhibiting HMG-
CoA reductase, (b) bisphosphonates, which interfere with the isoprenoid pathway in the step catalyzed by farnesyl diphosphate
synthase, (c) zaragozic acids and quinuclidines, inhibitors of squalene synthase (SQS), which catalyzes the ﬁrst committed step
in sterol biosynthesis, (d) allylamines, inhibitors of squalene epoxidase, (e) azoles, which inhibit C14α-demethylase, and (f)
azasterols, which inhibit Δ24(25)-sterol methyltransferase (SMT). Inhibition of this last step appears to have high selectivity for
fungi and trypanosomatids, since this enzyme is not found in mammalian cells. We review here the IC50 values of these various
inhibitors, their eﬀects on the growth of trypanosomatids (both in axenic cultures and in cell cultures), and their eﬀects on
protozoan structural organization (as evaluted by light and electron microscopy) and lipid composition. The results show that
the mitochondrial membrane as well as the membrane lining the protozoan cell body and ﬂagellum are the main targets. Probably
as a consequence of these primary eﬀects, other important changes take place in the organization of the kinetoplast DNA network
and on the protozoan cell cycle. In addition, apoptosis-like and autophagic processes induced by several of the inhibitors tested led
to parasite death.
Copyright © 2009 W. de Souza and J. C. F. Rodrigues. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Sterols are constituents of the cellular membranes that
are essential for their normal structure and function. In
mammalian cells, cholesterol is the main sterol found in the
various membranes. However, other sterols predominate in
eukaryotic microorganisms such as fungi and protozoa. In
the case of trypanosomatids, for many years cholesterol was
considered to be the major sterol. This was due to the fact
that all biochemical analyses were undertaken in protozoa
grown in complex media containing either brain, heart, or
liver extracts and bovine serum. When the ﬁrst biochemical
analysis of lower trypanosomatids grown in chemically
deﬁned medium was carried out, it became clear that they
synthesizeergosterolandnotcholesterol[1].Subsequently,it
was shown that the trypanosomatids incorporate cholesterol
from the culture medium or from the blood of infected
animals through a typical endocytic process involving, in the
case of epimastigotes of Trypanosoma cruzi, the formation of
endocytic vesicles in the ﬂagellar pocket and the cytostome
[2, 3].
It is now well established that an important metabolic
pathway in fungi and in members of the Trypanosomatidae
family is the sterol biosynthesis (SB) pathway. In these2 Interdisciplinary Perspectives on Infectious Diseases
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Figure 1: Molecular structures of cholesterol and ergosterol. The
arrowsindicatethepartsofthemoleculeswhichhavebeenshownto
be essential for the growth of mammalian cells (cholesterol), fungi,
and trypanosomatids (ergosterol and 24-methyl sterols).
organisms, this pathway produces a special class of sterols,
including ergosterol and other 24-methyl sterols, that is,
required for their growth and viability, but is absent from
mammalianhostcells[4,5].Cholesterolandergosteroldiﬀer
in a few minor ways, as shown in Figure 1; cholesterol has
only one double bond (Δ5(6)) in the B ring and has a
fully saturated side chain without a methyl group at C24.
It has been shown that some parts of the sterol molecule
are important for its activity in cellular membranes. In the
tetracyclic nucleus, the 3β–OH is obligatory for growth,
whereas the presence of methyl groups at C14 or C4 do
not allow growth. These two characteristics are essential for
both cholesterol and ergosterol to support growth. However,
certain characteristics of ergosterol that are absent in the
cholesterol molecule, such as the presence of two double
bonds in the B ring of the steroid nucleus, the presence
of a β methyl at position 24, and the double bond at C22
in the side chain are essential for the growth of fungi and
trypanosomatids.
The main sterols of the trypanosomatids comprise Δ5,7-
compounds belonging to the C28-ergostane (24-methyl or
methylene) or the C29-stigmastane (24-ethyl or ethylidine)
groups [6–9]. In Leishmania amastigotes and promastigotes,
the predominant sterol includes ergosta-5,7,24(241)-trien-
3β-ol (5-dehydroepisterol), although ergosta-118 7,24(241)-
dien-3β-ol (episterol) and ergosta-5,7,22-trien-3β-ol (ergos-
terol,themajorfungalsterol)arepresentinsmalleramounts.
Stigmastane-related sterols comprise 5% of the total sterols
inpromastigotes;whichcangoashighas20%inamastigotes
of some species [9–12]. In contrast, T. cruzi epimastigotes
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Figure 2: Schematic representation of main morphologies found
during the life cycle of some members of the Trypanosomatidae
family in the invertebrate host (insect) and vertebrate host (mam-
mal).
contain around 40% ergosterol and ergosta-5,7-dien-3β-ol,
and an appreciable amount, around 30%, of stigmasta-5,7-
dien-3β-ol, and stigmasta-5,7,22-trien-3β-ol [8, 13]. In the
case of amastigote forms, the sterol content is completely
diﬀerent since T. cruzi apparently does not produce Δ5,7-
sterols, which are replaced by ergosta-7-en-3β-ol and 24-
ethylidinecholest-7-en-3β-ol, indicating the absence of Δ5-
desaturase activity [14]. The content of sterols in Try-
panosoma brucei diﬀers from other trypanosomatids, where
the bloodstream form contains predominantly cholesterol
incorporatedfromthemediumthroughareceptor-mediated
endocytic process, which apparently suppresses de novo
synthesis of C28-sterols [15], even though it has mRNA
coding for enzymes involved in ergosterol biosynthesis [16].
In the procyclic form, the sterol content is diﬀerent from
the bloodstream form, with the major component in the
total membranes being ergosterol, with some amount of
cholesterol [16].
In the context of this review describing the eﬀect of sterol
biosynthesis inhibitors in members of the Trypasonomatidae
family, it is important to show a schematic representationInterdisciplinary Perspectives on Infectious Diseases 3
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Figure 3: The biosynthesis of ergosterol and cholesterol showing the main steps, the enzymes involved, and the known inhibitors.
of the main developmental stages found in the invertebrate
host(insect)andvertebratehost(mammal)forTrypanosoma
brucei, Trypanosoma cruzi,a n dLeishmania spp (Figure 2)
[17–20].
2. Comparison of the SterolBiosynthesis
PathwaysinMammals, Fungi,
andTrypanosomatids
A comparative schematic diagram of the sterol biosynthesis
pathway in eukaryotes is shown in Figure 3.A tl e a s t2 0
metabolic steps are necessary to synthesize such sterols
as cholesterol and ergosterol, with some steps involving
speciﬁc enzymes that diﬀer between mammalian cells and
microorganismssuchasfungiandtrypanosomatids.Someof
these enzymes have been extensively studied, both as targets
for the development of new drugs that interfere with parasite
growth without severe eﬀects on host cells and also as a
means of reducing the high levels of endogenous cholesterol
in mammalian cells.
The carbon skeleton of the sterol molecule is derived
from acetyl-CoA, with the exception to the presence of the
C24 methyl group in the ergosterol side chain. The ﬁrst4 Interdisciplinary Perspectives on Infectious Diseases
reactions in the biosynthetic pathway involve condensation
of two acetyl-CoA units to form acetoacetyl-CoA, followed
by the addition of a third unit to form 3-hydroxy-3-
methylglutaryl-CoA (HMG-CoA), which is then reduced by
NADPH to give mevalonic acid. These three steps comprise
the mevalonate pathway and are catalyzed by the cytosolic
enzyme acetoacetyl-CoA thiolase, and two mitochondrial
enzymes in yeasts and trypanosomatids, HMG-CoA syn-
thase, and HMG-CoA reductase [21–23]. By contrast, the
initial steps of cholesterol biosynthesis in mammalian cells
occur mainly in the cytosol, with the later steps occurring in
the endoplasmic reticulum (ER). On the other hand, several
of the enzymes have been reported to exist in peroxisomes
and in glycosomes [23–25].
After the mevalonate pathway, the next steps constitute
the isoprenoid pathway. Isoprenoids are the mostdiverse and
abundant compounds present in nature, and are essential
components of all organisms due to a variety of roles in
diﬀerent biological processes. First, mevalonate is converted
to isopentenyl diphosphate (IPP) by two phosphorylation
reactions followed by one decarboxylation. Subsequently,
isomerization of IPP by isopentenyl diphosphate isomerase
produces dimethylallyl diphosphate (DMAPP). After that,
longer isoprenoids are formed by a consecutive condensa-
tion of IPP with DMAPP and geranyl diphosphate (GPP)
to produce the 15-carbon isoprenoid compound known
as farnesyl diphosphate (FPP) in two reactions catalyzed
by the enzyme farnesyl diphosphate synthase (FPPS). All
these reactions together constitute the isoprenoid pathway,
which is present in almost all organisms investigated so
far [25]. FPP, which is the last product of isoprenoid
biosynthesis, is the substrate for enzymes catalyzing the ﬁrst
committed step for the biosynthesis of sterols, ubiquinones,
dolichols, heme A, and prenylated proteins. The enzymes
involved in the isoprenoid pathway are located in diﬀer-
ent subcellular compartments such as the cytosol [26],
mitochondria [27, 28], plastids in plant cells [26], and
the peroxisome in animals [29]. For example, in Leish-
mania major, FPPS is located in the cytosol [30], while
in Toxoplasma gondii it appears partially in the mitochon-
drion without any co-localization in rhoptries or apicoplast
[31].
After the isoprenoid pathway, the next two reactions
comprise the ﬁrst committed step in sterol biosynthesis.
These are catalyzed by the enzyme squalene synthase, which
promotes a head-to-head condensation of two molecules
of farnesyl diphosphate to produce squalene. In the ﬁrst
reaction, presqualene pyrophosphate (PPP) is produced by
the loss of an inorganic pyrophosphate. This is converted
to squalene in the second reaction in presence of NADPH,
an essential cofactor required to drive this conversion [32].
In mammalian cells and in yeasts, squalene synthase is
associated with the endoplasmic reticulum [33]. In L. major,
its localization is still controversial. The presence of the
signal sequences PTS1 and PTS2, typical of glycosomal
proteins, indicates localization to the glycosome [34], while
biochemical analysis of subcellular fractions of T. cruzi
and Leishmania spp. showed that it could be found in the
mitochondrion and microsomal fractions [35–37].
After production of squalene, sterol biosynthesis con-
tinues with the synthesis of 2,3-oxidosqualene (or squalene
epoxide) in a reaction catalyzed by the enzyme squalene
epoxidase. This is the ﬁrst step in the conversion of the
30-carbon chain squalene to the tetracyclic sterol skeleton.
Squalene epoxidase is the ﬁrst enzyme in the pathway that
requires molecular oxygen, and this reaction is performed
by a microsomal complex consisting of a ﬂavoprotein with
NADPH cytochrome C reductase activity, and a terminal
oxidase that is not of the cytochrome P-450 family [38].
In a reaction that is considered to be one of the most
complex in the sterol pathway, 2,2-oxidosqualene cyclase
cyclizes the intermediate 2,3-oxidosqualene to lanosterol,
the initial precursor of all steroid structures formed by
mammals, fungi, and trypanosomatids.
After the cyclization of 2,3-oxidosqualene to form
lanosterol, several sequential transformations occur to form
cholesterol in mammals and ergosterol in trypanosomatids
and fungi. Some of these reactions are common to all
eukaryotes, whereas others are exclusive to each organism,
with diﬀerences also between trypanosomatids and fungi.
One of the earliest steps in the lanosterol path-
way is the demethylation of the ring system at the
C14 position in a two-stage oxidative reaction cat-
alyzed by a cytochrome P-450-containing monooxyge-
nase enzyme known as lanosterol-14α-methyl demethylase
(C14α-demethylase) [38].
Removal of the 14α-methyl by C14α-demethylase gener-
ates a Δ8(14) unsaturated sterol with a double bond at the C14
position. This unsaturation needs to be removed to produce
Δ5 sterols in two consecutive reactions catalyzed by the
enzyme Δ8(14)-reductase with NADPH as cofactor. In several
fungi, this removal is essential, because the subsequent
enzymes in the pathway do not metabolize this unnatural
sterol. However in some fungal species such as Candida
albicans [38, 40], and also L. amazonensis [11]a n dT. cruzi
[42–44], it is metabolized by the C4-demethylase enzymes
and Δ24-methenylase to form Δ14 fecosterol.
After removal of the C4 and C14 methyl groups and
the methenylation of the side chain, the next reaction in
the sequence is the isomerization of the double bonds in
fecosterol in a reversible reaction catalyzed by the Δ7-Δ8
isomerase that does not require cofactors such as NADPH.
One of the most important stages of ergosterol biosyn-
thesis that does not exist in the synthesis of cholesterol is the
addition of a methyl group at the C24 position in the sterol
side chain. Depending on the microorganism, this occurs
early after the production of lanosterol, as observed in L.
amazonensis [11], or at the level of zymosterol (which does
not have the C4 and C14 methyl groups in the structure)
as found in several fungi [45]a n ds o m eLeishmania spp.
[46]. The methyl group is transferred from S-adenosyl-L-
methionine (SAM) to C-24 of Δ24 sterols to produce Δ24(28)-
sterols in some reactions catalyzed by the S-Adenosyl-L-
methionine:Δ24-sterol methyltransferase (EC 2.1.1.43; 24-
SMT).24-SMTisa150000daltonmembrane-boundprotein
that is present in plants, fungi, and trypanosomatids, but
is absent in mammalian sterol biosynthetic systems; thus
it may constitute an interesting target for the developmentInterdisciplinary Perspectives on Infectious Diseases 5
of antifungal and antitrypanosomal agents. Cell fraction-
ation studies have suggested that 24-SMT is located in
the glycosomes and in the mitochondrion [35]. However,
immunoﬂuorescence and electron microscopic observations
using antibodies generated against the recombinant protein
showed that 24-SMT is located in the endoplasmic reticulum
and in translucent vesicles that presumably belong to the
endocytic pathway [47].
3. Available Drugs that Interferewith
the SterolBiosyntheticPathway
Currently, there are several known drugs that interfere with
sterol biosynthesis which are used to treat diseases such as
high cholesterol in humans and fungal infections. Table 1
shows the representative compounds distributed in diﬀerent
classes, some of which are commercially available.
Statin is one of the main classes of the sterol biosynthesis
inhibitors (SBIs), which act on the mevalonate pathway
by the inhibition of HMG-CoA reductase. They have been
widely used for cholesterol reduction in humans [38]. A
drawback of the statins is their eﬀect on the synthesis
of isoprenoid compounds that are essential for several
cellular events. Atorvastatin, widely used for treatment of
hyperlipidemia, is one example of this class of drugs [48].
Bisphosphonate is another important class that interferes
with the isoprenoid pathway inhibiting the step catalyzed
by farnesyl diphosphate synthase (FPPS). They are used for
thetreatmentofdiﬀerentboneresorptiondiseases,including
osteoporosis, Paget’sdisease,hypercalcemiacausedbymalig-
nancy, and tumor metastases in bone [49]. Alendronate and
risedronatearetwoexamplesofbisphosphonatesusedforthe
treatmentofosteoporosis andotherbone resorption diseases
[49].
Zaragozic acids and quinuclidines are known inhibitors
ofsqualenesynthase(SQS),whichcatalyzestheﬁrstcommit-
ted step in sterol biosynthesis. This is a very attractive target
because its inhibition does not interfere with isoprenoid pro-
duction and intermediate metabolites that are formed can be
readily metabolized and excreted [50]. SQS has been under
intense scrutiny with the aim of developing new cholesterol-
lowering agents for humans. Previous experimental stud-
ies with animals have demonstrated the eﬀectiveness of
quinuclidine-based SQS inhibitors such as 3-(biphenyl-4-
yl)-3-hydroxyquinuclidine [BPQ-OH] as cholesterol- and
triglyceride-lowering agents [51–53].
Allylamines are known inhibitors of squalene epoxidase.
One good example is terbinaﬁne, which has been shown
to be a potent compound against fungi, showing both oral
and topical eﬃcacy. Terbinaﬁne inhibits squalene epoxidase
leading to a depletion of ergosterol. Importantly, it does not
inhibit the mammalian enzyme [38].
Azoles are important inhibitors of C14α-demethylase,
and since they are eﬀective against most fungal diseases,
they are presently considered to be the most important
antifungal compounds in use. Ketoconazole, one of the ﬁrst
azoles developed, was intensely used for several years. More
recently, however, four new commercially available triazoles
have been shown to be much more eﬀective: ﬂuconazole,
itraconazole, voriconazol, and posaconazole.
The last class of ergosterol biosynthesis inhibitors com-
prisestheazasterols,whichinhibitΔ24(25)-sterolmethyltrans-
ferase (SMT). Inhibition of this step appears to have high
selectivity for fungi and trypanosomatids since this enzyme
is not found in mammalian cells. Antifungal activities of
azasterols have been described for Candida spp. [38, 39],
Pneumocystis carinii [54], and Paracoccidioides brasiliensis
[55].
In conclusion, based on the comments made above it
is clear that further exploration of the sterol biosynthesis
pathway is highly relevant to the treatment of both chronic
diseases, such as hypercholesterolemia, and infectious dis-
eases causedby fungi and trypanosomatids. Therefore,drugs
known to inhibit enzymes of the sterol biosynthesis pathway
should be tested against all these diseases. Indeed, several
drugsdevelopedeithertoreducecholesterollevelsinhumans
or to treat fungal diseases have been tested with some
success against trypanosomatids, as will be discussed below.
We also believe that new drugs shown to be active against
trypanosomatids should be tested on fungi as well as in
mammals.
4. Effects of SB Inhibitorson
TrypanosomatidGrowth
In T. cruzi, inhibitors of HMG-CoA reductase such as
mevinolin (lovastatin) have been tested in vitro and in vivo.
Against the extracellular proliferative epimastigote forms,
mevinolin produced a dose-dependent reduction of the
growth rate up to 25μM. In the intracellular proliferative
amastigote forms only very modest eﬀects were observed
up to 0.75μM, above which a signiﬁcant eﬀect was also
observed in the mammalian host cells. In intracellular
amastigotes, it has been shown that supplementation of
mevinolinwithketoconazolegivesasynergisticeﬀect,sothat
lowerconcentrationsofazolesbecomemoreeﬀective.Onthe
other hand, the combination of mevinolin with terbinaﬁne
produced an additive eﬀect, whereas the combination of
mevinolin, terbinaﬁne, and ketoconazole showed again a
synergistic eﬀect on amastigotes [56]. These results together
indicate that a combination of drugs acting in consecutive
steps of the sterol biosynthesis pathway may be a promising
approach for the treatment of diseases caused by some
pathogenic protozoa.
Bisphosphonates have been tested in vivo and in vitro
against diﬀerent protozoan parasites, including Leishmania
spp., T. cruzi, T. brucei, Plasmodium falciparum,a n dT. gondii
[57–59]. More than 50 new compounds were tested in diﬀer-
ent protozoan parasites, some of them presenting IC50 values
lower than 1μM[ 60, 61]. In addition, to conﬁrm that the
isoprenoid enzymes are involved in the inhibition, they were
also tested on the isolated L. major, T. cruzi,a n dT. gondii
farnesyl diphosphate synthase enzymes (LmFPPS, TcFPPS,
and TgFPPS). A potent inhibition of the enzyme’s activities
indicated that some of them are speciﬁc for inhibition of
the isoprenoid pathway, thus validating this pathway as an6 Interdisciplinary Perspectives on Infectious Diseases
Table 1: Representative compounds that interfere with sterol synthesis in eukaryotes, fungi and trypanosomatids.
Molecular structure Name Class Mechanism of action
NH
O NO H
F
OH OH O
Atorvastatin Statin Inhibitor of the HMG-CoA Reductase. Used
to treat hyperlipidemia in humans
OH
H2PO3 PO3H2
NH2
Alendronate Bisphosphonate Inhibitor of the farnesyl diphosphate
synthase (FPPS). Used to treat osteoporosis
and diﬀerent bone resorption diseases
N
OH
BPQ-OH Quinuclidine Inhibitor of the squalene synthase (SQS),
acting in the cholesterol and ergosterol
biosyntheses
N
CH3 H3C
CH3
CH3
Terbinaﬁne Allylamine Inhibitor of the squalene epoxidase. Used
for a long time to treat fungal infections
N
N
N
N N
O
N
OH
N N O
F F
O Posaconazole Azole Inhibitor of the C14α-demetilase. One of
the triazole used to treat fungal infections
OH
HN
HO
22,26-azasterol Azasterol Inhibitor of the Δ24(25)-sterol
methyltransferase, one enzyme presents
exclusively in the ergosterol biosynthesis
interesting and selective drug target for these parasites. Gar-
zoni et al. [62] reported that risedronate showed a selective
eﬀect against Trypanosoma cruzi, leading to complete growth
arrest and lysis at 150μM for epimastigotes. Complete
destruction of intracellular amastigotes was observed at
100μM risedronate, thus preventing the development of T.
cruzi infections in murine muscle heart or in Vero cells [62].
In trypanosomatids and fungi, there are several works
describing the potent and selective activity of zaragozic acids
and quinuclidines [35–37, 63–68]. For example, ER-119884
and E5700, two novel quinuclidine derivatives produced by
Eisai Co. (Tokyo, Japan), have been shown to be potent anti-
Trypanosoma and Leishmania agents in vitro, leading to a
dramatic depletion of the parasite’s endogenous sterols, thatInterdisciplinary Perspectives on Infectious Diseases 7
is, associated with an intense antiproliferative activity [36,
37]. Figures 4(a)–4(d) shows the antiproliferative eﬀect of
E5700 (Figures 4(a) and 4(c)) and ER-119884 (Figures 4(b)
and 4(d)) in promastigotes and intracellular amastigotes of
Leishmania amazonensis. These compounds are very potent
against both forms of the life cycle, presenting MIC values
of 30 and 10nM for promastigote, and 2.0 and 0.5nM
for intracellular amastigotes [37]. When compared with
the minimal concentration that aﬀects macrophages, these
values are, respectively, 100000 and 25000 fold greater than
the corresponding IC50, indicating that they are selective
against the parasite without any eﬀect in the host cells.
In Leishmania, Vannier-Santos et al. [70] showed that
terbinaﬁne is able to interfere with the growth of pro-
mastigotes and intracellular amastigotes, inducing dramatic
changes in their structural organization, especially in the
mitochondrion. For terbinaﬁne, the IC50 values were around
1μMforpromastigotesand100nMforintracellularamastig-
otes. However when in combination with ketoconazole,
which also interferes with ergosterol biosynthesis, the values
decreased to around 1nM for intracellular amastigotes,
indicating once more that the approach of inhibiting mul-
tiple steps of this pathway is a promising alternative for
chemotherapy [70].
In trypanosomatids, azoles have been used in vitro
against T. cruzi and Leishmania. Drugs such as D0870 and
posaconazol were tested in vitro and in vivo with positive
and interesting results, and also have a potent eﬀect against
acute and chronic experimental Chagas’ disease [69, 71–
75]. Ketoconazole was also tested alone or in combination
with other sterol biosynthesis inhibitors [42, 44, 71, 76].
The IC50 of Posaconazole for T. cruzi epimastigotes and
amastigotes was 3 and 0.25nM, respectively. However when
in combination with amiodarone, a K+ and Ca2+ channel
antagonist,theypresentedsynergisticeﬀectswithafractional
inhibitory concentration(FIC) of 0.42μM[73].Amiodarone
was also tested in Leishmania mexicana, having an IC50
similar to that found for T. cruzi, due to alterations in the
physiology of the mitochondrion and acidocalcisomes [77].
The eﬀects of azasterols on T. cruzi [4, 42–44, 78],
Leishmania [5, 11, 47, 78, 79], and T. brucei [16]h a v eb e e n
extensively studied. The antifungal activities of azasterols
against Candida spp., P. carinii [54], and P. brasiliensis
[55] have also been described. We have shown that several
azasterols are active against L. amazonesis with IC50s in the
submicromolar to nanomolar range, indicating that this step
has potential as a chemotherapeutic target [11, 78, 80].
Furthermore, when in combination with azoles they are even
more eﬀective, and sometimes acting synergistically [43].
5. Effects of SB Inhibitorson
the Ultrastructureof Trypanosomatids
It has been shown that ergosterol biosynthesis inhibitors
induce dramatic alterations in the ultrastructure of sev-
eral organelles [11, 37, 64, 66, 70, 74–76, 78–81]. These
alterations occur mainly in the mitochondrion-kinetoplast
complex, the endoplasmic reticulum, the Golgi complex,
nucleus, multivesicular structures, lipidic inclusions, the
contractile vacuole, and also in the plasma membrane
covering the cell body, and the ﬂagellum.
The mitochondrion-kinetoplast complex has been
shown to constitute an important organelle target of drugs
that inhibit sterol biosynthesis. It is important to point out
that T. cruzi and Leishmania have only one highly ramiﬁed
mitochondrion distributed throughout the protozoan body
(Figure 5(a))(reviewedin[82]).TreatmentofL.amazonensis
with diﬀerent azasterols induced mitochondrion alterations
such as a disorganization of the mitochondrial membranes
(Figures 5(b)-5(c)) followed by an intense swelling and loss
of the matrix contents (Figures 5(b)-5(d))[ 11, 76]. These
alterations in the mitochondrion were also observed after
treatment of T. cruzi and L. amazonensis with terbinaﬁne,
ketoconazole, and ICI195,739 [70, 74–76]. The swelling
is dramatic and the mitochondrion appears to occupy the
whole cytosol in epimastigotes treated with ketoconazole
(Figures 6(a)-6(b)). The mitochondrial alterations were
conﬁrmed by measuring the mitochondrial membrane
potential in digitonin-permeabilized parasites [79]. On the
other hand, the inhibitors did not aﬀect the macrophage’s
mitochondria, which can be visualized using JC-1, a
cationic mitochondrial vital dye [37]. Most probably all
these morphological changes are due to modiﬁcations
in the composition of the mitochondrial membranes
due to interference with the synthesis of ergosterol and
accumulation of intermediate metabolites [83]. Lipid
analysis performed in epimastigotes of T. cruzi showed that
the mitochondrion has a diﬀerent lipid composition when
compared with mammalian cells, including the presence of
ergosterol, thus explaining the potent eﬀect of SB inhibitors
on its ultrastructure and physiology [84].
One characteristic feature of the unique mitochondrion
of trypanosomatids is the presence of a complex network
of DNA localized in a portion of the mitochondrion. This
network is located just below the basal bodies from which
the ﬂagellum is formed, and is known as the kinetoplast
(reviewed in [85]). The kinetoplast DNA is organized as
thousands of concatenated minicircles and a few maxi-
circles. It was shown that after treatment with E5700, an
SQS inhibitor, alterations were observed in the kinetoplast
structure of L. amazonensis. In treated cells, the kinetoplast
appeared completely disorganized relative to its normal
structure (Figure 6(c)). These alterations probably result
from changes that take place in the organization of the
inner mitochondrial membrane, that is, connected to the
kinetoplast DNA network.
Alterations in the nuclear membrane, Golgi complex and
endoplasmic reticulum were also observed after treatment
withdiﬀerentSBinhibitors(Figures7(a)–7(c)).Thepresence
of a multivesicular body associated with the trans-Golgi net-
w o r kc a nb es e e ni nFigure 7(b) (star), thus suggesting alter-
ations in the secretory pathway. Furthermore, Figure 7(c)
(stars) also shows the presence of some vacuoles resembling
autophagosomes, thus suggesting the occurrence of cell
death by autophagy (reviewed in [86–88] ) .T h ep r e s e n c eo f
large vacuoles containing membrane proﬁles, endoplasmic
reticulum forming myelin-like ﬁgures or engulﬁng a part of8 Interdisciplinary Perspectives on Infectious Diseases
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Figure 4: (a)-(b) Growth curves of promastigotes and (c)-(d) intracellular amastigotes of Leishmania amazonensis treated with two
potent squalene synthase inhibitors, E5700 and ER-119884. The graphics are reproduced with permission from [37] American Society for
Microbiology.
the cytoplasm, and damaged organelles supports the idea
that an autophagy-like process takes place in these cells
(Figures 8(a)-8(b)).
Recent studies using various microscopy techniques have
shown that trypanosomatids possess a structure located
close to the ﬂagellar pocket identiﬁed as a contractile
vacuole (reviewed in [89]). This structure became much
more evident in L. amazonensis (Figures 9(a)-9(b))a n d
T. cruzi epimastigotes [64] treated with SB inhibitors. As
observedbydiﬀerentialinterferencecontrastmicroscopy,the
treated cells appeared rounded and swollen (Figure 9(a)),
suggesting osmotic changes, thus explaining the presence of
a prominent contractile vacuole. These changes may be due
to alterations in the plasma membrane’s permeability to ions
induced by the complete depletion of sterols and sterol-like
molecules, which is likely to lead to signiﬁcant changes of the
physicochemical properties of the lipid bilayer [90].
Another important alteration observed after treatment
with SB inhibitors is the presence of several lipid droplets
displaying variable morphology, as shown in Figures 10(a)-
10(b). The formation of these structures is probably due
to accumulation of lipid precursors. The images showed a
large variation in the electron density of the structures, sug-
gesting that diﬀerent types of lipids are accumulated. Some
appeared very dense after postﬁxation with osmium tetrox-
ide (Figure 10(a)). Others, however, appeared as electron-
lucent structures (Figure 10(b), large arrows and stars). They
are surrounded by a typical monolayer of phospholipidsInterdisciplinary Perspectives on Infectious Diseases 9
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Figure 5: Ultrathin sections of L. amazonensis promastigotes control (a) and treated with azasterols, known inhibitors of the Δ24(25)-sterol
methyltransferase (b)–(d). (a) General overview of an untreated-parasite showing a normal ultrastructure of the mitochondrion (M),
kinetoplast (k), ﬂagellum (F) and nucleus (N). (b)–(d) Treated-parasites presenting severe alterations in the mitochondrion structure such
as a disorganization of the internal membranes ((b) and (c), arrowheads) and an intense and evident mitochondrial swelling with loss of the
matrix content (b)–(d). Bars 0.5μm.
(high magniﬁcation in Figure 10(b)). These lipid droplets
could be also identiﬁed by ﬂuorescence microscopy using
the neutral lipid marker Nile Red [37]. Lipid droplets
were also observed in L. major null mutants for important
enzymes of the sphingolipid biosynthesis pathway [91, 92],
and in T. cruzi after perturbation of the sphingolipid content
[93]. On the other hand, they also accumulated when
epimastigotesweretreatedwithdiﬀerentclassesofinhibitors,
including cytoskeletal inhibitors [94], indicating that lipid
body formation can occur as a consequence of perturbations
in parasitic functions not related to lipid biosynthesis.
Alterations in the plasma membrane lining the cell
body, ﬂagellar pocket and ﬂagellum were also observed,
but the morphological changes varied according to the
inhibitor (Figures 11(a)-11(b)). When the parasites where
incubated with azasterols, alterations in the ﬂagellar pocket
were predominant (Figure 11(a)), while SQS inhibitors
induced alterations mainly in the membrane lining the cell
body (Figure 11(c)-11(d)) and sometimes in the ﬂagellar
membrane (Figure 11(b))[ 64]. These diﬀerent phenotypes
suggestthatthe three domains of the plasma membrane have
distinct lipid compositions. On the other hand, the presence
of membrane blebs could be related to apoptosis-like death
[86].
It is well known that in trypanosomatids there is a
close connection between the plasma membrane lining the
cell body and the subpellicular microtubules, and that the
spatial distribution of these microtubules is responsible for
the maintenance of the protozoan’s shape (reviewed in
[95]). Immunoﬂuorescence microscopy of tubulin-stained
trypanosomes treated with an SBI revealed changes in the
shape of the cell and in the distribution of the subpellicular
microtubules, probably due to alterations in the sterol
composition of the plasma membrane [37]. Figures 12(a)–
12(d) show the eﬀect of ER-119884, an SQS inhibitor,
on the cytoskeleton of L. amazonensis promastigotes. The
changes were also seen by transmission electron microscopy
(Figure 11(d)).
Recent observations show that SBIs also interfere with
the protozoan cell cycle. Using ﬂuorescence microscopy of
cells stained with DAPI to label the nucleus and kinetoplast,
as well as transmission electron microscopy, it was shown
that ER-119884 and BPQ-OH interfere dramatically with the
cell cycle, inducing several abnormal phenotypes, including
cells with multiple nuclei, kinetoplasts, and ﬂagella (Figures
13(a)–13(d)). The eﬀect on the cell cycle was already evident
after 24 hours of incubation in the presence of the inhibitors,
and the number of cells containing abnormal numbers of
ﬂagella, kinetoplasts, and nuclei increased with time [37].
There are at least two possible explanations for these eﬀects:
(i)thecellsdonot completecelldivisionduetothedepletion
of essential endogenous sterols, which control the dynamics
of the membrane but are also key regulators of the cell
cycle [96, 97], or (ii) the organization of the cytoskeleton
necessary for the completion of cytokinesis, which requires
interactions with the nuclear membrane, is in some way
aﬀected by SQS inhibitors. In addition, SBI also induced
signiﬁcant alterations in the trypanosomatids’ nuclei.
A signiﬁcant number of treated cells showed abnormal
chromatin condensation (Figure 14), indicating a process of
cell death by apoptosis (reviewed in [86–88]).
All these alterations discussed here indicate that sterols
play an essential role in a signiﬁcant number of cellular
processes, including the cell cycle, cell death, and the10 Interdisciplinary Perspectives on Infectious Diseases
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Figure 6: Trypanosoma cruzi epimastigotes treated with keto-
conazole, an inhibitor of the C14α-demetilase (a)-(b), and L.
amazonensis promastigotes treated with E5700, an inhibitor of the
squalene synthase (c) showing an intense mitochondrial swelling
(a)-(b)and alterations in the kinetoplast structure ((c), arrowhead).
K, kinetoplast; M, mitochondrion. (a)-(b) Images are reproduced
with permission from [74] American Society for Microbiology.
Bars, 0.5μm.
maintenance of the membrane’s structure, stability, and
function.
6. EffectsofSBInhibitorsonLipidComposition
It is now well established that SB inhibitors lead to the
accumulation of intermediates of the ergosterol biosynthesis
N
(a)
GC
(b)
M
(c)
Figure 7: L. amazonensis promastigotes treated with azasterols
(a)-(b), and ER-119884 (c) showing alterations in the nuclear
membrane ((a), arrowhead), in the Golgi complex ((b), arrow-
head), and in the endoplasmic reticulum ((c), arrowhead). In
the Figures 6(b) and 6(c), the presence of a multivesicu-
lar bodies and autophagosome-like structures (stars) could be
related with a remodeling process of damaged organelle by
autophagy. GC, Golgi complex; M, mitochondrion; N, nucleus.
Bars, 0.5μm.
pathway (reviewed in [4]). Treatment of T. cruzi epimastig-
otes with mevinolin, an inhibitor of HMG-CoA reductase,
led to a signiﬁcant reduction in the presence of ergosterol-
like molecules, with a concomitant increase in exogenous
cholesterol [56].
Incubation of the parasites with bisphosphonates,
inhibitors of the farnesyl diphosphate synthase (FPPS),Interdisciplinary Perspectives on Infectious Diseases 11
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Figure 8: Promastigotes treated with quinuclidine and azasterol, respectively, showing the presence of structures related with autophagy
such as a large vacuole containing many membrane proﬁles ((a), arrowheads), and a myelin-like ﬁgures involving part of the cytosol
((b), arrowhead). Star indicates the presence of a possible contractile vacuole near the ﬂagellar pocket. A, autophagosome; F, ﬂagellum;
K, kinetoplast; M, mitochondrion; N, nucleus. (a) This image is reproduced with permission from [66]E l s e v i e r .B a r s ,0 .25μm.
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Figure 9: (a) Diferential interference contrast (DIC) microscopy and (b) transmission electron microscopy showing the presence of
a prominent contractile vacuole (arrows) near the ﬂagellar pocket after treatment of L. amazonensis promastigotes with quinuclidine
inhibitors. In the left panel it is possible to observe a rounded and swollen parasite that probably indicates osmotic changes due alterations
in the plasma membrane’s permeability. F, ﬂagellum; K, kinetoplast. Bars, 5μm and 0.5μm, respectively.
induces an accumulation of isopentenyl diphosphate (IPP)
and inhibits the formation of farnesyl diphosphate (FPP).
Consequences of this inhibition include a decrease in the
level of protein prenylation, and reduced production of
moleculessuchasdolichols,ubiquinones,hemea,andsterols
(reviewed in [58]).
The inhibition of squalene synthase (SQS) induces a
total depletion of squalene, endogenous ergosterol, and
other 24-methyl sterols, and these are completely replaced
by exogenous cholesterol [35–37]. This potent eﬀect in
the sterol composition is consistent with the inhibition
of SQS enzyme in concentrations near the nanomolar to
subnanomolar range, in a reaction that is noncompetitive
with the substrate [37].
Treatment of L.mexicanapromastigoteswithterbinaﬁne,
a potent inhibitor of squalene-2,3-epoxidase, results in the
accumulation of squalene, and a reduction in the amount
of endogenous C28-a n dC 29-sterols [98]. In T. cruzi epi-
mastigotes the same treatment led to the depletion of sterols
and accumulation of phosphorylated hydrocarbons, with a
lower amount of squalene when compared with Leishmania
[99]. The K+ and Ca+2 channel antagonist amiodarone also
induces the inhibition of squalene epoxidase in T. cruzi and
L. mexicana, leading to an accumulation of squalene and
complete depletion of 24-methyl sterols such as ergosterol
and 5-dehydroepisterol [73, 77].
Incubation of the parasites in the presence of azoles,
which inhibit C14α-demethylase, led to the replacement of
normal endogenous sterols by various 14α-methyl sterols. In
this situation, the ﬁrst sterol that accumulates in promastig-
otes of Leishmania is 4α,14α-dimethyl-dimethylzymosterol;
however, after a long exposure this sterol molecule could be
metabolized by 24-SMT, producing sterols alkylated at C-
24, or demethylated at C-4 by C4α-demethylase to produce12 Interdisciplinary Perspectives on Infectious Diseases
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Figure 10: Treatment of promastigotes with ER-119884 induces the accumulation of several lipid droplets in the cytosol, sometimes
appearingasanelectrondensestructureduetoosmiumtetroxideconcentration((a)-(b),smallarrows),andasaclassiclipidbodysurrounded
by a phospholipid monolayer ((b), large arrows). At high magniﬁcation (stars), it is evident that the structures are completely diﬀerent,
probably indicating a distintic nature of the lipids that accumulate in these inclusions. M, mitochondrion; N, nucleus. All images are
reproduced with permission from [37] American Society for Microbiology. Bars, 0.5μm.
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Figure 11: Ultrathin sections of L. amazonensis promastigotes treated with diﬀerent sterol biosynthesis inhibitors showing severe alterations
intheplasmamembranelining(a)theﬂagellarpocket,(b)theﬂagellum,and(c)-(d)thecellbody.In(d)itispossibletoobserveabreakdown
in the plasma membrane and release of the subpellicular microtubules (arrowhead). Star in (c) shows a classic lipid body. F, ﬂagellum; FP,
ﬂagellar pocket; k, kinetoplast; M, mitochondrion. Images are reproduced with permission from [79] (a), and [66] (b), (d) Elsevier. Bars,
0.25μm (a)–(c) and 0.5μm (d).Interdisciplinary Perspectives on Infectious Diseases 13
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Figure 12: DIC microscopy (left panel) and immunoﬂuorescence microcospy (right panel) of L. amazonensis promastigotes control
(a)-(b) and treated with ER-119884 (c)-(d). The labeling corresponds to the cytoskeleton constituted mainly by tubulin, revelead here
by using of an Alexa 488-labeled secondary antibody. The black arrow in DIC image corresponds to the cell body which sometimes
appeared changed and rounded as compared to the control parasites, while the white arrows point to several tubulin clusters that
accumulated in the cytosol after treatment. All images are reproduced with permission from [37] American Society for Microbiology. Bars,
5μm.
4-desmethylsterol [11, 46, 100]. In T. cruzi epimastig-
otes and amastigotes, the accumulating 14α-methylsterol
is lanosterol, particularly its C-24 alkylation product (24-
methylenedihydrolanosterol) [5, 14, 69, 71–75, 99, 101].
Unlike Leishmania, demethylation at C4 seems to be very
restricted in T. cruzi, and the C4α-demethylase has higher
speciﬁcity for sterols after the removal of the 14α-methyl. On
the other hand, treatment with SCH 56592 (posaconazole)
also causes an accumulation of squalene, possibly indicating
that some regulatory step involved in squalene cyclization is
regulatedbyhighamountsoflanosterolandits24-methylene
derivatives [72].
The C-24 transmethylation reaction catalyzed by 24-
SMT in trypanosomatids is inhibited by various azasterols
that have a nitrogen substitution in the side chain. This leads
to a depletion of C28-sterols such as ergosterol, episterol,
and 5-dehydroepisterol, which are then replaced by large
amounts of zimosterol and cholesterol ingested from the cul-
ture media [11, 42, 43, 102] through the endocytic pathway
[3]. Furthermore, a simultaneous incubation with azasterol
and ketoconazole induces an accumulation of lanosterol,
4,14-dimethyl-zymosterol, and 14-methyl-zymosterol [11,
42, 43], indicating that the mechanism of action of 24-
SMT in trypanosomatids is similar to that observed in fungi,
yeasts, and plants [32, 38, 44, 103–105]. These results also
indicate that in some trypanosomatids, 24-SMT can use
zymosterol or its 14-methyl or 4,14-dimethyl derivatives as
substrates. In the case of fungi, the substrate for 24-SMT
is restricted to zymosterol [32, 38]. On the other hand,
experiments exposing Leishmania spp. to low concentration
azasterol for a long time showed that they are able to survive
by modulating biosynthesis to use C27-sterols as substrates
for 24-SMT [102]. Thus, these biochemical analyses indicate
that in the case of sterol biosynthesis it is better to use
combination therapy to inhibit more than one step in order
to completely eliminate all the sterol substrates, particularly
of the 24-SMT enzyme, which participates in essential
reactions.
It is important to point out that in all biochemical
analyses of the lipid composition of trypanosomatids after
drug treatment, a signiﬁcant accumulation of cholesterol is
observed in both T. cruzi and Leishmania spp., indicating
that the parasites try to compensate for the absence of
endogenous sterols. It is also clear that 24-methyl and/or 24-
ethyl sterols are essential for the maintenance of membrane
structure and function, as well as other vital cellular process
like the cell cycle.14 Interdisciplinary Perspectives on Infectious Diseases
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Figure 13: DIC microscopy ((a)-(b), left panel), ﬂuorescence with DAPI ((a)-(b), right panel) and transmission electron microscopy (c)-
(d) of treated-promastigotes to evidenciate the alterations in the cell cycle after treatment with BPQ-OH and ER-119884. (a) Control cells
present a correct number of kinetoplast (white arrow), nucleus (arrowhead), and ﬂagellum (black arrow), one of each for a unique cell. (b)
After treatment, the number of these organelles is completely alterated and it is possible to ﬁnd cells with one ﬂagellum (black arrow), four
kinetoplast (white arrows), and one nucleus (arrowhead). (c)-(d) Alterations in the cell cycle can also be evidenced by transmission electron
microscopy with the appearance of cells with several nuclei and kinetoplasts. K, kinetoplast; N, nucleus. These images are reproduced with
permission from [37] American Society for Microbiology (a), (b), (d), and from [66] Elsevier (c). Bars, 5μm (a)-(b), and 0.5μm (c)-(d).
7. Effects of SB Inhibitorsin
ExperimentallyInfectedAnimalsand
Perspectives for Human Therapy
Several of the SB inhibitors have been tested using murine
models of Chagas’ disease, leishmaniasis, and malaria. Treat-
ment of acute Chagas’ disease with mevinolin (lovastatin)
in combination with ketoconazole led to the elimination of
circulating parasites and complete protection against death
in the murine model [56].
BisphosphonateswerealsotestedinacuteChagas’disease
as well as in leishmaniasis experimental models. In Leish-
mania infections, recent studies showed that pamidronate
is able to promote a radical cure of experimental cutaneous
leishmaniasis in mice [105], and also that it is active in vivo
against L. donovani by intravenous administration [106].
Furthermore, in vivo studies using the murine model of
acute Chagas’ disease showed that treatment with 1mg/kg
risedronate per day for 7 days induced a more than 90%
reduction in parasitemia and signiﬁcantly increased the ani-
mals’ survival. On the other hand, at higher concentrationsInterdisciplinary Perspectives on Infectious Diseases 15
N
Figure 14: Leishmania amazonensis promastigote treated with
sterolbiosynthesisinhibitorsshowingacondensationofthenuclear
chromatin, a characteristic feature of the apoptosis-like cell death
process. N, nucleus. Bar, 0.5μm.
(up to 10mg/kg per day), risedronate led to a reduction of
parasitemiaandmortalitywithnotoxiceﬀectsforthetreated
animals [107].
Inhibitors of squalene synthase such as ER-119884 and
E5700 were also tested in a murine model of Chagas’ disease,
revealing that E5700 is able to provide full protection against
death and to completely suppress parasitemia, with no
toxicity to the host [36].
Some azoles were also tested against T. cruzi and
Leishmania spp. with interesting results. D0870, a bis-triazole
derivative, showed a potent eﬀect, preventing death and
inducingparasitologicalcurein70to90%ofanimalsinacute
and chronic murine models of Chagas’ disease [71, 108].
SCH 56592 (posaconazole), which is one of the new triazole
derivatives, has been tested against Chagas’ disease [72, 109]
and leishmaniasis [110]. In the acute Chagas’ disease model,
43 doses of ≥1 0 m g / k go fb o d yw e i g h t / d a yp r o m o t e d8 5
to 100% survival, with 90 to 100% cure of the animals as
veriﬁed by parasitological, serological and PCR-diagnostics.
By contrast, ketoconazole at 30mg/kg/day gave only a 60%
survival rate and a 20% cure rate. [72]. In the chronic
phase, the results were also positive, with 85% of the animals
protected from death and 75% parasitologically cured. In
addition, the combination of posaconazole with amiodarone
produced a delay in the development of parasitemia after a
highrateofinfectionmice,andinmicewithalowerinfection
rate, the survival and cure were higher when compared with
posaconazole alone [73]. Amiodarone alone also led to a
decrease in parasitemia and a 40% increase in the survival of
the infected animals [73]. On the other hand, in cutaneous
leishmaniasis, treatment with 60 and 30mg/kg/day, of SCH
56592 was highly eﬃcacious, and the higher dose was
superior to amphotericin B at a dose of 1mg/kg/day [110].
In visceral leishmaniasis due to L. donovani infection, treated
miceshowed asigniﬁcant reductioninparasite burdeninthe
liver and spleen compared to untreated mice [110].
In vivo studies with 22,26-azasterol, one of the most
potent inhibitors of 24-SMT, have shown that it has selective
antiparasitic activity in a murine model of acute Chagas’
disease [43].
8.Perspectives
It is clear that the sterol biosynthesis pathway plays a key
role in the metabolism of eukaryotic cells. The observation
that compounds found in several steps of this metabolic
pathway plays essential roles in several basic physiological
processes spurred several groups to further analyze this
metabolic pathway. From the parasitological point of view,
it will be important to test new drugs developed for other
medical purposes, such as control of blood cholesterol levels
in humans, against trypanosomatids. The same assumption
is valid for drugs interfering with the SB pathway in fungal
cells. On the other hand, since trypanosomatids, fungi
and mammals share several steps of the SB pathway, the
trypanosomatids may constitute a useful biological system
for the screening of candidate SB inhibitors, and thereby
facilitatethesearchforcholesterol-controldrugsforhumans.
Finally, we expect that new studies will appear providing a
better characterization of the last steps of the SB pathway,
especiallythoseinvolvedintransformationofzimosterolinto
ergosterol.
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